FY2024 EPS Estimates for Microbix Biosystems Inc. Lowered by Analyst (TSE:MBX)

Microbix Biosystems Inc. (TSE:MBX – Get Rating) – Research analysts at Bloom Burton dropped their FY2024 EPS estimates for Microbix Biosystems in a research report issued on Monday, May 15th. Bloom Burton analyst A. Borovina now forecasts that the company will post earnings per share of $0.05 for the year, down from their prior forecast of $0.06. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.01 per share.

Microbix Biosystems Price Performance

TSE MBX opened at C$0.42 on Thursday. The company has a market capitalization of C$58.15 million, a PE ratio of 34.00 and a beta of 0.14. Microbix Biosystems has a 12-month low of C$0.30 and a 12-month high of C$0.57. The firm’s 50 day moving average is C$0.38 and its 200-day moving average is C$0.40. The company has a quick ratio of 5.57, a current ratio of 6.32 and a debt-to-equity ratio of 25.43.

Microbix Biosystems Company Profile

(Get Rating)

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably test ingredients for immunoassays and quality assessment and proficiency testing controls (QAPs) that support sample collection devices.